The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.60
Bid: 17.40
Ask: 17.80
Change: -0.50 (-2.76%)
Spread: 0.40 (2.299%)
Open: 17.64
High: 17.64
Low: 17.60
Prev. Close: 18.10
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

7 May 2015 07:00

RNS Number : 4268M
Nanoco Group PLC
07 May 2015
 

 

For immediate release

7 May 2015

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Appointment of Chief Financial Officer

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is pleased to announce the appointment of David Blain as Chief Financial Officer.

 

David, who will join Nanoco and the Company's Board on 3 August 2015, is a chartered accountant with considerable operational, commercial and strategic experience gained at a number of businesses quoted on the London Stock Exchange. He is joining Nanoco from the role of Chief Financial Officer at Inspired Capital plc, an AIM traded finance provider.

 

After qualifying as a chartered accountant David joined the Newcastle office of Price Waterhouse (now PwC), where he worked for nine years in audit and business advisory services. He then spent 11 years as the Finance Director of Drew Scientific Group plc, a medical diagnostics company on the main market. His next role was at the AIM traded IT business, eg Solutions plc, after which he became Chief Financial Officer of Renovo Group plc, the Manchester-based biotechnology company that later became Inspired Capital plc.

 

Michael Edelman, Nanoco's Chief Executive Officer, commented: "We are delighted that David Blain is joining the Nanoco management team as Chief Financial Officer at this exciting stage in the Company's development. David has a wealth of financial and commercial experience and we look forward to his contribution to the future growth of Nanoco.

 

"I would also like to thank Mark Sullivan, who has provided outsourced accountancy services to Nanoco for many years, for his role since October last year as Interim Chief Financial Officer."

 

 

There are no further disclosures required under paragraph 9.6.13 of the UKLA's Listing Rules.

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Mark Sullivan, Interim Chief Financial Officer

Canaccord Genuity - Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Mark Whitmore

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Simon Atkinson

Richard Bootle

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALIFFEEEIDIIE
Date   Source Headline
16th Jul 20214:41 pmRNSSecond Price Monitoring Extn
16th Jul 20214:35 pmRNSPrice Monitoring Extension
15th Jul 20217:00 amRNSNon-dilutive loan note subscription
5th Jul 20217:30 amRNSDevelopment Agreement
28th Jun 20217:00 amRNSLitigation update and non-dilutive debt facility
10th Jun 202111:33 amRNSBlocklisting Six-Monthly Return
24th May 202112:20 pmRNSHolding(s) in Company
20th May 20217:00 amRNSLitigation Update
13th May 20217:00 amRNSProject Extension
12th May 20217:00 amRNSLitigation Update
6th May 20213:28 pmRNSHolding(s) in Company
30th Mar 20217:00 amRNSInterim Results
29th Mar 20217:00 amRNSLitigation Update
26th Mar 20214:41 pmRNSSecond Price Monitoring Extn
26th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 20213:36 pmRNSAmendment to Executive Director Service Terms
16th Mar 20212:30 pmRNSNotice of Results
10th Feb 20214:40 pmRNSSecond Price Monitoring Extn
10th Feb 20214:35 pmRNSPrice Monitoring Extension
25th Jan 20214:41 pmRNSSecond Price Monitoring Extn
25th Jan 20214:35 pmRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202011:40 amRNSBlocklisting Six-Monthly Return
3rd Dec 202012:10 pmRNSResult of AGM
3rd Dec 20207:00 amRNSAGM Statement
25th Nov 20207:00 amRNSGrant Funding Award for Life Sciences Project
17th Nov 20205:50 pmRNS2020 Annual Report and Notice of AGM
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
21st Oct 20203:16 pmRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSPreliminary Results
7th Oct 20207:00 amRNSNotice of Results
25th Sep 20204:36 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSDirectorate Changes
21st Jul 202011:25 amRNSHolding(s) in Company
20th Jul 202012:35 pmRNSHolding(s) in Company
16th Jul 20202:15 pmRNSDirector/PDMR Shareholding
16th Jul 20207:00 amRNSResult of Fund Raise
15th Jul 20205:20 pmRNSPrimaryBid.com Offer
15th Jul 20205:17 pmRNSTrading Update and Proposed Fundraising
14th Jul 20209:55 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSLitigation Funding Agreement
2nd Jul 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20204:36 pmRNSPrice Monitoring Extension
30th Jun 202010:06 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSBlocklisting Six-Monthly Return
5th Jun 20204:41 pmRNSSecond Price Monitoring Extn
5th Jun 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.